MAPT and Alzheimer disease: In early-stage AD, APOE4 homozygotes with BCHE-K had the lowest levels of glial activation, neurodegeneration, and tau pathophysiology (Table 2), whereas indices of these pathologies were presumably higher in APOEɛ4 heterozygotes with BCHE-K.